Guinea Pig Serum Sterile
Datasheet is currently unavailable. Try again or CONTACT US
Datasheet

Guinea Pig Serum Sterile

D105-00-0050 D105-00-0100 D105-00-0500 D105-00-1000
50 mL 100 mL 500 mL 1 L
ELISA, FC, IHC, Other, WB
Have a Question? Ask a Specialist
$665.00 /Per Item
$992.00 /Per Item
$3,713.00 /Per Item
$6,334.00 /Per Item
50 mL $665.00
100 mL $992.00
500 mL $3,713.00
1 L $6,334.00
Availability: Ships in approximately 14 days Availability: Ships in approximately 14 days Availability: Ships in approximately 14 days Availability: Ships in approximately 14 days
Shipping info:

$50.00 to US & Canada for most products. Final costs are calculated at checkout.

Description

Background

Guinea Pig Serum is used as a supplement to cell culture media. Guinea Pig Serum is also suitable for use as a component of bioassays, immunoassays or enzyme assays. Guinea Pig Serum provides a broad spectrum of macromolecules, carrier proteins for lipoid substances and trace elements, attachment and spreading factors, low molecular weight nutrients, and hormones and growth factors that promote cell growth and health. Be certain to maintain Good Cell Culture Practice, and maintain sterility of cultures that require media supplementation. Guinea Pig Serum is ideal for investigators in Cancer, Immunology, and Cell Biology research.

Application Note

pH: normal Immunoelectrophoresis: normal Hemoglobin: normal IgG Concentration: normal

Storage Condition

Store container at -20° C prior to opening. Avoid cycles of freezing and thawing. Use aseptic technique to maintain sterility when opening product.

GUINEA PIG SERUM (sterile) - D105-00-0050
Guinea Pig serum for cell culture, cell culture grade guinea pig serum, sterile serum from guinea pig.
ELISA, FC, IHC, Other, WB
Guinea Pig
Serum
Mixed
Guinea Pig - Mixed
Sterile
Liquid (sterile filtered)
Dry Ice
Expiration date is one (1) year from date of opening.
75mg/ml by Refractometry
None
None
None
Miller AD et al. FoxP3+ regulatory T cells are not important for rotavirus clearance or the early antibody response to rotavirus. (2014)
Kanungo S et al. Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India. (2014)
Eisenstein TK et al. Anandamide and Δ9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. (2007)
Yotsushima K et al. Effects of fatty acid-free bovine serum albumin and fetal calf serum supplementing repair cultures on pre- and post-warm viability of biopsied bovine embryos produced in vitro. (2004)
Hsieh MH et al. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms. (2000)
Toma H et al. Immunohistochemical distribution of c-Kit-positive cells and nitric oxide synthase-positive nerves in the guinea-pig small intestine. (1999)
Sawant-Mane S et al. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. (1996)
Edens RE et al. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. (1994)
Sawant-Mane S et al. Antibody of patients with Guillain-Barré syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype. (1994)
Beck LA et al. Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. (1988)
Lin YS et al. Inhibition of antibody production from the plasmacytoma cell line MOPC-315 by staphylococcal enterotoxin B-induced T-suppressor cells. (1986)
Whitlow MB et al. Penetration of C8 and C9 in the C5b-9 complex across the erythrocyte membrane into the cytoplasmic space. (1985)
Ishii Y et al. Translation of human macrophage activating factor (for glucose consumption) mRNA in Xenopus laevis oocytes. (1985)
Ramm LE et al. Size distribution and stability of the trans-membrane channels formed by complement complex C5b-9. (1983)
Ramm LE et al. Elimination of complement channels from the plasma membranes of U937, a nucleated mammalian cell line: temperature dependence of the elimination rate. (1983)
Rosenfeld SI et al. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins. (1983)
Imagawa DK et al. Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives. (1983)
Jordan RE et al. Antithrombin in vertebrate species: conservation of the heparin-dependent anticoagulant mechanism. (1983)
Ramm LE et al. Size of the transmembrane channels produced by complement proteins C5b-8. (1982)
Ramm LE et al. Transmembrane channel formation by complement: functional analysis of the number of C5b6, C7, C8, and C9 molecules required for a single channel. (1982)
Campos-Neto A. Immune response gene control of antibody specificity. (1982)
Bucy RP et al. Ir gene control of the immune response to insulins. I. Pork insulin stimulates T cell activity in nonresponder mice. (1981)
Ramm LE et al. Life-span and size of the trans-membrane channel formed by large doses of complement. (1980)
Cines DB et al. Effect of anti-P1A1 antibody on human platelets. I. The role of complement. (1979)
Campos-Neto A. T-cell regulation of restricted B-cell responses. (1978)
MacGregor RR et al. Impaired granulocyte adherence in multiple myeloma: relationship to complement system, granulocyte delivery, and infection. (1978)
Schreiber AD et al. Effect of C3b inactivator on monocyte-bound C3-coated human erythrocytes. (1978)
Baltz M et al. Low-dose antigenic signals to helper lymphocytes. (1977)
Steshenko PP et al. Antigen recognition: the specificity of an isolated T lymphocyte population. (1977)
Yaron A et al. Immune Ascites in the Guinea Pig: Specificity of Cells and Antibody in an Induced Peritoneal Exudate. (1977)
Baltz M et al. Down regulation in B lymphocytes: low dose signals. (1977)
Schreiber AD et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. (1976)
Kenna MA et al. Effect of papain on the interaction between human monocytes, erythrocytes, and IgG. (1975)
Twomey SL et al. Shortened Radioimmunoassay for Human Growth Hormone. (1974)

Invalid lot number

If you need help finding your CofA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.